Yesterday we commented (by request) on a paper by Klotz et al. suggesting that initial treatment with the LHRH antagonist degarelix might have benefits compared to initial treatment with an LHRH agonist such as leuprolide or goserelin acetate. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adverse, Degarelix, event, LHRH agonist, outcome, trreatment | 1 Comment »
One of our regular readers has asked us to comment on a paper suggesting the possibility of “significant improvement” in various outcomes for men initially treated with the LHRH antagonist degarelix as compared to the LHRH agonists leuprolide acetate and goserelin acetate. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, benefit, Degarelix, LHRH, outcome, survival | 1 Comment »
According to a media release issued by the National Institute for Clinical Excellence (NICE) in the UK, it has issued new draft guidance recommending treatment with degarelix (Firmagon) as an option for men with prostate cancer-related spinal metastases who are at risk for spinal cord compression. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: compression, Degarelix, NICE, spinal cord | 6 Comments »
According to an announcement from the European Association for Urology (EAU) earlier today, data from a recently completed trial demonstrate that degarelix is “non-inferior” to the LHRH agonist goserelin acetate + the antiandrogen bicalutamide at reducing prostate volume in men with advanced hormone- dependent prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant, Degarelix, neoadjuvant, radiation therapy | 2 Comments »
The question of whether an LHRH antagonist (such as degarelix) is really a better first-line hormone therapy than an LHRH agonist (e.g., leuprolide acetate) is still not fully answered. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, Degarelix, leuprolide, LHRH | Leave a comment »
In today’s news reports we comment on:
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: adiponectin, adjuvant radiation, biochemical failure, cost, Degarelix, obesity, positive surgical margin, risk, tumor volume | Leave a comment »
Before the coming of the PSA test, urologists used to use serum acid phosphatase levels (usually) and serum alkaline phosphatase (S-ALP) levels (less commonly) to assess the status of men at risk for or under treatment for metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: Degarelix, serum alkaline phosphatase | Leave a comment »
Apparently Ferring Pharmaceuticals has finally been able to get Firmagon® approved as the new trade (brand) name for degarelix (their new LHRH antagonist) here in the USA. This is the same brand name as is used in Europe. Who knows why it took so long! The media release doesn’t say.
In other news reports today we comment on studies dealing with:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: Degarelix, Height, quality of care, survival, tallness, vitamin B-6 | Leave a comment »
A review article and three different sets of editorial comments have just been published in Oncology. They lay out the opinions of several specialists on the potential uses of degarelix — a recently approved, “second-generation” LHRH antagonist — in the management of prostate cancer. All the relevant articles are available in full on line. … READ MORE …
Filed under: Management, Treatment | Tagged: Degarelix | Leave a comment »
Ferring Pharmaceuticals has announced the company’s intent to initiate a randomized, controlled, multi-center trial of degarelix used as intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer who have rising serum PSA levels after previous curative therapies. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Degarelix, intermittent androgen deprivation therapy. IADT | Leave a comment »
There are a significant number of relatively long-term news items in today’s report. Of most immediate interest to the majority of prostate cancer patients and educators we include reports on:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, curcumin, Degarelix, focal therapy, nanoparticles, PROMIS, sexual function, TRAIL | 3 Comments »
We reported last December that the Committee for Medicinal Products for Human Use had adopted a positive opinion and had recommended marketing authorization for degarelix, a second-generation LHRH receptor antagonist, for the treatment of patients with advanced, hormone-dependent prostate cancer.
According to a media release from Ferring Pharmaceuticals earlier today, the European Union has now finalized approval of degarelix for clinical use in Europe.
Filed under: Drugs in development | Tagged: approval, Degarelix | Leave a comment »
We had previously noted the approval of degarelix in Europe on December 23rd.
It has been kindly pointed out to us that late on Christmas Eve the US Food and Drug Administration also approved the second generation LHRH antagonist degarelix for clinical use and marketing. … READ MORE …
Filed under: Drugs in development | Tagged: Degarelix | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 